Vera Therapeutics, Inc. (VERA) SEC Filings & Earnings Calls

Regulatory approval and commercial launch risks remain.

“sBLA submission planned for Q4 2026; FDA approval not guaranteed.”

Commercialization Execution Risk

“We have never successfully commercialized a product before and may lack the necessary expertise, personnel and resources to successfully commercialize any product on our own or together with potential collaborators.” · word for word

Dependence on Single Product

“TRUTAKNA is our only FDA-approved product and the success of our business depends, in part, on its successful commercialization.” · word for word

Significant Milestone Payment Obligations

“The Company is obligated to pay Ares additional milestone payments, including $10.0 million upon the first filing of an approval application in the European Union, and other potential milestone payments of up to $131.5 million in aggregate upon the achievement of regulatory filing and approval milestones for other geographic regions and indications, and up t” · word for word

High Cash Burn Rate

“We have incurred net losses since inception, and expect to record limited revenue from product sales during the third quarter of 2026. We expect to continue to incur net losses at least until we have one or more approved products that achieve commercial success.” · word for word

Significant net loss and cash burn; commercial launch costs will increase expenses.

“Net loss $109.5M in Q2; operating cash burn $206.8M in H1”

Dependence on full approval and sBLA submission; potential delays or negative outcomes.

“sBLA submission expected Q4 2026; full approval expected 2027”

Forward-looking statements caution that actual results may differ; full approval contingent on eGFR results.

“Pending these results, the Company plans to submit a supplemental Biologics License Application for full approval.”

Clinical and Regulatory Dependency

“We are substantially dependent on the success of our product candidates. If we are unable to complete development of, obtain regulatory approval for and commercialize our product candidates in one or more indications and in a timely manner, our business, financial condition, results of operations and prospects will be significantly harmed.” · word for word

Operating Losses and Capital Needs

“We have incurred net losses since inception, and have never generated revenue from product sales. We expect to continue to incur net losses at least until we have one or more approved products that achieve commercial success.” · word for word

Net loss increased significantly due to pre-commercial investments.

“net loss of $121.0 million, or a net loss per diluted share of $1.69, compared to a net loss of $51.7 million” · word for word

Clinical Trial Failure Risk

“atacicept has been the subject of clinical trials by prior sponsors, including a Phase 2 trial in systemic lupus erythematosus (SLE), that missed its primary endpoint in the overall study population.” · word for word

Need for Additional Capital

“We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs of our product candidates or future commercialization efforts.” · word for word

Competitive Pressure

“Among emerging therapies, we consider our most direct competitors with respect to atacicept in IgAN to be approved products: the reformulated steroid from Asahi Kasei Corp., the anti-APRIL monoclonal antibody from Otsuka Pharmaceuticals, both the complement inhibitor and selective ETA receptor antagonist from Novartis, and the endothelin and angiotensin II r” · word for word

Historical Net Losses

“We had net losses of $299.6 million, $152.1 million and $96.0 million for the fiscal years ended December 31, 2025, 2024, and 2023, respectively.” · word for word

Debt Covenant Restrictions

“The terms of our loan agreement place restrictions on our operating and financial flexibility.” · word for word

Loss of key legal officer without immediate replacement may impact regulatory and legal oversight.

“Departure of Chief Legal Officer, no successor named.”

Clinical trial success reduces pipeline risk; safety profile favorable

“Incidence of adverse events balanced; fewer serious adverse events with atacicept (n=1 [0.5%]) than placebo (n=11 [5%]); no deaths”

No approved products; reliance on atacicept

“We have completed a limited number of clinical trials for our lead product candidate, atacicept, and have no products approved for commercial sale.” · word for word

Significant operating losses and accumulated deficit

“We have incurred net losses since inception, and have never generated revenue from product sales.” · word for word

Need for substantial additional capital

“We will require substantial additional capital to finance our operations.” · word for word

Net loss increased significantly to $80.3M from $46.6M, driven by higher R&D expenses and clinical trial costs.

“Net loss $80.3M vs $46.6M prior year; operating cash burn $171.1M in 9 months.”

Regulatory and commercial risk: atacicept BLA submission and FDA approval are not guaranteed; any delays or negative outcomes could impact stock.

“BLA submission expected Q4 2025; potential approval and launch in 2026; clinical-stage biotech with no approved products.”